We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+9.63%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$59.8B
AUM Growth
+$5.07B
(+9.3%)
Cap. Flow
+$518M
Cap. Flow
% of AUM
0.87%
Top 10 Holdings %
Top 10 Hldgs %
18.08%
Holding
2,992
New
38
Increased
2,358
Reduced
537
Closed
43
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$68M |
| 2 |
Truist Financial
TFC
|
+$55.9M |
| 3 |
ServiceNow
NOW
|
+$33.3M |
| 4 |
Uber
UBER
|
+$21.4M |
| 5 |
Las Vegas Sands
LVS
|
+$15.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$119M |
| 2 |
STI
SunTrust Banks, Inc.
STI
|
+$55.9M |
| 3 |
Apple
AAPL
|
+$48.3M |
| 4 |
iShares TIPS Bond ETF
TIP
|
+$22M |
| 5 |
VIAB
Viacom Inc. Class B
VIAB
|
+$16.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Financials | 15.53% |
| 3 | Healthcare | 13.38% |
| 4 | Consumer Discretionary | 10.07% |
| 5 | Industrials | 9.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BPMC
1176
DELISTED
Blueprint Medicines
BPMC
| $5.7M | 0.01% |
71,108
+3,058
| +4% | +$229K |
|
1177
Credit Acceptance
CACC
$6.15B
| $5.69M | 0.01% |
12,854
+196
| +2% | +$86.3K |
|
1178
8x8 Inc
EGHT
$292M
| $5.68M | 0.01% |
310,537
+18,112
| +6% | +$350K |
|
1179
AAR Corp
AIR
$5.71B
| $5.67M | 0.01% |
125,740
+5,621
| +5% | +$244K |
|
1180
Starwood Property Trust
STWD
$5.92B
| $5.66M | 0.01% |
227,838
+4,320
| +2% | +$106K |
|
|
ADAM
1181
Adamas Trust
ADAM
$848M
| $5.65M | 0.01% |
226,584
+34,505
| +18% | +$855K |
|
1182
MGE Energy Inc
MGEE
$3.02B
| $5.64M | 0.01% |
71,571
+986
| +1% | +$76K |
|
1183
PRA Group
PRAA
$666M
| $5.63M | 0.01% |
155,182
+8,335
| +6% | +$295K |
|
1184
Sprouts Farmers Market
SFM
$8.28B
| $5.63M | 0.01% |
290,921
+1,244
| +0.4% | +$24.1K |
|
1185
Wayfair
W
$15.3B
| $5.63M | 0.01% |
62,242
+2,442
| +4% | +$228K |
|
1186
Shake Shack
SHAK
$2.61B
| $5.62M | 0.01% |
94,409
+7,911
| +9% | +$569K |
|
1187
Worthington Enterprises
WOR
$2.78B
| $5.62M | 0.01% |
216,083
+2,977
| +1% | +$70K |
|
1188
Edgewell Personal Care
EPC
$1.27B
| $5.6M | 0.01% |
180,835
-1,484
| -0.8% | -$47.9K |
|
|
SFBS
1189
ServisFirst Bancshares
SFBS
$4.92B
| $5.6M | 0.01% |
148,589
+8,171
| +6% | +$292K |
|
1190
Eagle Bancorp
EGBN
$849M
| $5.58M | 0.01% |
114,843
+5,361
| +5% | +$243K |
|
1191
NETSCOUT
NTCT
$3.07B
| $5.58M | 0.01% |
231,891
+1,556
| +0.7% | +$36.8K |
|
|
OPI
1192
DELISTED
Office Properties Income Trust
OPI
| $5.58M | 0.01% |
173,553
+11,564
| +7% | +$370K |
|
1193
Avis
CAR
$4.91B
| $5.57M | 0.01% |
172,875
+1,198
| +0.7% | +$35.9K |
|
1194
Axos Financial
AX
$5.88B
| $5.57M | 0.01% |
184,007
+9,631
| +6% | +$281K |
|
1195
LeMaitre Vascular
LMAT
$2.37B
| $5.54M | 0.01% |
153,954
+2,811
| +2% | +$97K |
|
1196
Pricesmart
PSMT
$6.08B
| $5.53M | 0.01% |
77,899
+5,266
| +7% | +$378K |
|
1197
Axalta
AXTA
$7.76B
| $5.52M | 0.01% |
181,713
+3,370
| +2% | +$99.3K |
|
1198
OSI Systems
OSIS
$3.9B
| $5.52M | 0.01% |
54,836
+4,251
| +8% | +$420K |
|
1199
InterDigital
IDCC
$7.98B
| $5.52M | 0.01% |
101,365
-790
| -0.8% | -$43.6K |
|
1200
Merit Medical Systems
MMSI
$5.11B
| $5.52M | 0.01% |
176,683
+12,771
| +8% | +$366K |
|
Similar funds
VAM
RhumbLine Advisers's Q4 2019 Portfolio in Review
As of Q4 2019, RhumbLine Advisers held 2,992 positions worth $59.8B, up 9.3% from $54.7B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Trading was light in Q4 2019: portfolio turnover was 2.7%. RhumbLine Advisers opened 38 new positions and exited 43, leaving the 2,992-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q4 2019 buy was Envista: 126,664 shares worth $3.75M.
- RhumbLine Advisers added most to Bristol-Myers Squibb in Q4 2019, an estimated $68M increase.
- RhumbLine Advisers's biggest Q4 2019 reduction was Apple, cutting an estimated $48.3M.
- RhumbLine Advisers fully exited Celgene Corp in Q4 2019, selling an estimated $119M.
- RhumbLine Advisers's ten largest holdings make up 18% of its $59.8B portfolio in Q4 2019.
- RhumbLine Advisers opened 38 new positions and closed 43 in Q4 2019.
- RhumbLine Advisers's portfolio value rose 9.3% quarter-over-quarter to $59.8B.
Based on RhumbLine Advisers's 13F filing for Q4 2019, filed 5 Feb 2020.